NASDAQ
36.82USD
-1.40 (-3.66%)
We have scored 27 news catalysts on Roivant Sciences Ltd. (ROIV) over the past 12 months. The biggest single-day move next to one of them came Feb 8, 2026, when ROIV closed +22.1%: “Roivant Sciences (NASDAQ:ROIV) Sets New 1-Year High – What’s Next?”. Coverage across the window leans positive (average ticker sentiment +0.30). Most of the impact sits in sector healthcare and price momentum.
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
26.6B
P/E
—
EPS
—
Beta
1.12
52W range
14.5-42.5
Day range
36.80–38.47
Open
37.99
Prev close
38.22
Volume
7.8M
Avg volume
7M
Dividend
0.00
IPO
2020-12-08
Daily OHLCV with SMA overlays and session pivots. Draw your levels and trendlines on it, or ask the AI analyst what the price is reacting to.
Suppliers, customers, partners and competitors, derived from what the news actually says about Roivant Sciences Ltd. — not a sector bucket. Click an edge to see the articles that established the link.
Suppliers, customers, partners and competitors of Roivant Sciences Ltd., taken from what the news actually said about them rather than from a sector bucket. The count is how many articles established each link.
Latest scored catalyst for ROIV: .
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Roivant Sciences Ltd. is a biopharmaceutical and healthcare technology company dedicated to discovering and advancing innovative therapeutic drugs. The firm's development pipeline targets a broad spectrum of diseases, including various forms of solid tumors and oncologic malignancies, hematological disorders like sickle cell disease and warm autoimmune hemolytic anemia, as well as rare conditions such as hypophosphatasia. Additionally, Roivant is developing treatments for immunological and dermatological ailments, including psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne, myasthenia gravis, thyroid eye diseases, and sarcoidosis, alongside tackling infections like staph aureus bacteremia. Founded in 2014, its operations are based in London, United Kingdom.
